Cargando…

Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence

BACKGROUND: Invasive lobular carcinomas (ILCs) account for 10–15% of all breast cancers. They are characterized by an elevated endocrine responsiveness and by a long lasting risk of relapse over time. Here we report for the first time an analysis of clinical and pathological features associated with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Conforti, Fabio, Pala, Laura, Pagan, Eleonora, Viale, Giuseppe, Bagnardi, Vincenzo, Peruzzotti, Giulia, De Pas, Tommaso, Bianco, Nadia, Graffeo, Rossella, Rocco, Elena Guerini, Vingiani, Andrea, Gelber, Richard D., Coates, Alan S., Colleoni, Marco, Goldhirsch, Aron
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937973/ https://www.ncbi.nlm.nih.gov/pubmed/31888717 http://dx.doi.org/10.1186/s13058-019-1234-9

Ejemplares similares

Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations()
por: Conforti, Fabio, et al.
Publicado: (2021)

Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis
por: Conforti, Fabio, et al.
Publicado: (2021)

Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials()
por: Pala, Laura, et al.
Publicado: (2023)

Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT
por: Pagani, Olivia, et al.
Publicado: (2020)

Improved adjuvant endocrine therapy for premenopausal women with endocrine responsive disease
por: Goldhirsch, Aron, et al.
Publicado: (2015)

Different effectiveness of anticancer immunotherapy in men and women relies on sex-dimorphism of the immune system
por: Conforti, Fabio, et al.
Publicado: (2018)

Successful treatment with avapritinib in patient with mucosal metastatic melanoma
por: Cocorocchio, Emilia, et al.
Publicado: (2020)

Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial
por: Johansson, Harriet, et al.
Publicado: (2016)

Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials
por: Conforti, F., et al.
Publicado: (2021)

Sex-based dimorphism of anticancer immune response and molecular mechanisms of immune evasion
por: Conforti, Fabio, et al.
Publicado: (2021)

Association of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials: A Systematic Review and Meta-analysis
por: Pala, Laura, et al.
Publicado: (2022)

Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer
por: Orlando, Laura, et al.
Publicado: (2006)

Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor–Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5
por: Dowsett, Mitch, et al.
Publicado: (2018)

High frequency of lobular breast cancer in distant metastases to the orbit
por: Raap, Mieke, et al.
Publicado: (2015)

Impact of autoimmune diseases on outcome of patients with early breast cancer
por: Criscitiello, Carmen, et al.
Publicado: (2016)

Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity
por: Torrisi, R, et al.
Publicado: (2008)

Collective invasion in ductal and lobular breast cancer associates with distant metastasis
por: Khalil, Antoine A., et al.
Publicado: (2017)

Factors that predict early treatment failure for patients with locally advanced (T4) breast cancer
por: Montagna, E, et al.
Publicado: (2008)

Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer
por: Torrisi, R, et al.
Publicado: (2007)

Adjuvant treatment for triple negative breast cancer with residual tumor after neo-adjuvant chemotherapy. A single institutional retrospective analysis
por: Bianco, Nadia, et al.
Publicado: (2021)

Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer
por: Ribi, K, et al.
Publicado: (2012)

Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date
por: Criscitiello, Carmen, et al.
Publicado: (2018)

EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Non–Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials
por: Conforti, Fabio, et al.
Publicado: (2020)

The 6th Milan Breast Cancer Conference, Milan, Italy, 16–18 June 2004
por: Gennari, Roberto, et al.
Publicado: (2005)

Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma
por: Nunes, Raquel, et al.
Publicado: (2021)

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
por: Goldhirsch, A., et al.
Publicado: (2011)

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
por: Goldhirsch, A., et al.
Publicado: (2009)

Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy
por: Montagna, Emilia, et al.
Publicado: (2020)

Extracellular Vesicles as an Endocrine Mechanism Connecting Distant Cells
por: Kita, Shunbun, et al.
Publicado: (2022)

Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX
por: Coates, Alan S, et al.
Publicado: (2012)

Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer
por: Du, Tian, et al.
Publicado: (2018)

Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes
por: Maisonneuve, Patrick, et al.
Publicado: (2014)

ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC)
por: Ferrando, Lorenzo, et al.
Publicado: (2023)

Advances in Early Breast Cancer Risk Profiling: From Histopathology to Molecular Technologies
por: Pescia, Carlo, et al.
Publicado: (2023)

International Web-based consultation on priorities for translational breast cancer research
por: Dowsett, Mitch, et al.
Publicado: (2007)

Systematic review and meta-analysis of post-progression outcomes in ER+/HER2− metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials
por: Munzone, E., et al.
Publicado: (2021)

Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
por: Coates, A. S., et al.
Publicado: (2015)

The use of fulvestrant, a parenteral endocrine agent, in intestinal obstruction due to metastatic lobular breast carcinoma
por: Tang, Jasmine YM, et al.
Publicado: (2008)

Solitary uterine metastasis of invasive lobular carcinoma after adjuvant endocrine therapy: a case report
por: Toyoshima, Masafumi, et al.
Publicado: (2015)

WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines
por: Sikora, Matthew J., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mkgkrl9nerkv80na5q98vpfjl7